Seed treatment can increase crop yield by 40%
Using rare earth permanent magnets, high-voltage electrostatic fields, and rare earth light source photon radiation technology, the seeds can produce biochemical effects, improve resistance to stress and resistance to pests and diseases, so as to achieve an average yield increase of 10.5%-36.4% for field crops, and a 10% increase for vegetables. 40% goal. Recently, this high-tech, low-carbon, energy-saving, environmentally-friendly, non-polluting high-tech project that has reached the international advanced level in the same field has settled in Jiangsu Bond Biological Technology Development Co., Ltd. in Nantong Economic Development Zone.
According to reports, in the past, equipment that used this technology to process seeds was imported from abroad, and the price was 8 to 10 times that of China. The company relies on technical support from the Chinese Academy of Sciences and Harbin Engineering University. After nearly 20 years of efforts, the intelligent physical seed processor developed uses techniques such as rare earth permanent magnets, high voltage electrostatic fields, and rare earth light source photon radiation to produce biochemical effects on seeds. The seeds germinate early and the seedlings are of high quality. The contents of fatty acids, sugars and total amino acids in the plants are higher than those of untreated seeds. The ability to resist stress and resist diseases and insect pests is improved, so that the average normal field crops are 10.5% to 36.4%. The goal of increasing output by 10% to 40% has filled the gaps in the country and won two national patents, reaching the international advanced level in the same field. The company has a designed annual production capacity of 10,000 units and has designed and processed more than 1 million tons of seed capacity per year.
Intermediates of Cladribine, Carvedilol, Lurasidone, olmesartan, Risedronate Sodium, Atazanavir, Saxagliptin, Dabigatran,Dapoxetine,Cefixime,Ceftaroline fosamil and etc.
In the short span of time, we have emerged as most promising pharmaceutical intermediates manufacturers, chemical intermediates and bulk drug intermediates suppliers. Our consistent supply, quality products and dedication towards clients have opened up many international avenues for our growth.
In addition, the company also can follow the customer's product needs custom synthesis services
MAIN API PRODUCTS USP/BP
|
PRODUCT NAME |
CAS NUMBER |
SPEVIFICATION |
|
Azithromycin |
117772-70-0 |
BEP |
|
Cefpirome Sulphate sterile |
84957-29-9 |
USP JP16 |
|
Ceftriaxone Sodium (Sterile) |
104376-79-6 |
USP31 |
|
Cefotaxime |
64485-93-4 |
USP30 |
|
Ciprofloxacin HCL |
85721-33-1 |
USP/BP |
|
Gentamicin sulphate |
1405-41-0 |
BP |
|
Levofloxacin |
100986-85-4 |
USP27 |
|
Lincomycin Hydrochloride |
859-18-7 |
EP6.0 |
|
Moxifloxacin Hydrochloride |
186826-86-8 |
USP31 |
|
Tigecycline |
220620-09-7 |
USP |
|
Linezolid |
165800-03-3 |
EP |
|
Dexamethasone |
50-02-2 |
USP/BP/EP |
|
Methylprednisolone |
83-43-2 |
USP/BP/EP |
|
Dexketoprofen trometamol |
156604-79-4 |
BP2008 |
|
Ibuprofen |
15687-27-1 |
BP |
|
Metamizol |
68-89-3 |
DAB |
|
Sulindac |
38194-50-2 |
USP/BP/EP |
|
Naproxcinod |
163133-43-5 |
USP28 |
|
Tripelennamine Hydrochloride |
154-69-8 |
USP28 |
|
Itraconazole |
84625-61-6 |
USP/BP |
|
Cytarabine |
147-94-4 |
USP31 |
|
Leucovorin Calcium |
1492-18-8 |
USP32 |
|
Valsartan |
137862-53-4 |
USP30 |
|
Telmisartan |
144701-48-4 |
USP31 |
|
Rosuvastatin Calcium |
147098-20-2 |
USP/BP |
|
Pitavastatin Calcium |
147526-32-7 |
USP/BP |
|
Fluvastatin |
93957-54-1 |
USP31 |
|
Vinpocetine |
42971-09-5 |
EP6.0 |
|
Atazanavir |
198904-31-3 |
BP |
|
Rosiglitazone |
122320-73-4 |
USP30 |
|
Esomeprazole Magnesium |
161973-10-0 |
USP/BP |
|
Topiramate |
97240-79-4 |
USP31 |
|
Fexofenadine HCl |
153439-40-8 |
Inhouse |
|
Bosentan |
147536-97-8 |
Inhouse |
|
D-Cysteine |
921-01-7 |
Inhouse |
|
D-Phenylalanine |
673-06-3 |
Inhouse |
|
Linagliptin |
668270-12-0 |
Inhouse |
|
Rivaroxaban |
366789-02-8 |
USP |
|
Saxagliptin |
361442-04-8 |
USP |
|
Vildagliptin |
274901-16-5 |
USP |
Major Pharmaceutical Intermediates
| Items Descripation | Structure | Application |
|
MICA ESTER CAS No: 246035-38-1 Purity: ≥98% |
 |
For Cefixime |
|
EHATA CAS No: 64485-82-1 Purity: ≥98% |
 |
For Ceftazidine |
|
2-Chloroadenine CAS No: 1839-18-5 |
 |
For Cladribine, Fludarabine et al |
|
Bicyclo(2,2,1)Heptane-2,3-di-exo-carboximide CAS No: 14805o-29-9 |
 |
For Lurasidne |
|
(R,R)-1,2-Bis(methanesulfonyloxy methyl)Cyclohexane CAS No: 186204-35-3 |
 |
For Lurasidone |
|
3-(Piperazin-1-yl)benzol[d] isothiazole CAS No: 87691-87-0 |
 |
For Lurasidone |
|
Trityl olmesartan CAS No: 144690-92-6 Purity: ≥98% |
|
For olmesartan |
|
3-Acetyl Pyridine CAS No: 350-03-8 |
|
For Risedronate Sodium |
|
3-(AceticAcid)pyridine HCL CAS No: 6419-36-9 |
 |
For Risedronate Sodium |
|
Risedronic Acid CAS No: 105462-24-6 |
 |
For Risedronate Sodium |
|
3-Hydroxy-1-adamantyl-D-Glycine CAS No: 709031-29-8 |
 |
For Saxagliptin |
|
(1s,3s,5s)-3-(aminocarbonyl)-2-azabicyclo(3,1,0) hexane-2-carboxylic acid tert-butyl ester CAS No: 361440-67-7 |
 |
For Saxagliptin |
|
(S)-N-Boc-3- hydroxy-adamantylglycine CAS No: 361442-00-4 |
 |
For Saxagliptin |
|
2-Azabicyclo[3.1.0] hexane-3-carbonitrile, (1s,3s,5s)- CAS No: 866083-42-3 |
 |
For Saxagliptin |
|
Ethyl 3-(pyridin-2-ylamino) propanoate CAS No: 103041-38-9 |
 |
For Dabigatran |
|
N-(4-Cyanophenyl) glycine CAS No: 42288-26-6 |
 |
For Dabigatran |
|
4-methylamino-3-nitrobenzoic Acid CAS No: 41263-74-5 |
 |
For Dabigatran |
|
S-3-Amino-3-phenylpropanoic acid ethyl ester HCL CAS No: 167834-24-4 |
 |
For Dapoxetine |
|
(S)-3-Amino-3-Phemylpropan -1-ol CAS No: 82769-76-4 |
|
For Dapoxetine |
|
(S)-3-Dimethylamino-3-Phemylpropanol CAS No: 82769-75-3 |
|
For Dapoxetine |
|
4-{4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-butynil}-α,α-dimethyl benzene acetic acid CAS No: 832088-68-3 |
For Fexofenadine HCl | |
|
Methyl 2-(4-(4-chlorobutanoyl)phenyl)-2-methylpropanoate CAS No:154477-54-0 |
|
For Fexofenadine HCl |
|
5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone CAS No 461432-22-4 |
|
For Dapagliflozin |
|
4-(5-Bromo-2-chlorobenzyl)phenyl ethyl ether CAS No :461432-23-5 |
|
For Dapagliflozin |
Mica Ester,Pharma Intermediates,Ciprofloxacin Hcl Uses,Active Pharmaceutical Ingredients
NINGBO VOICE BIOCHEMIC CO. LTD , https://www.pharma-voice.com